RESUMEN
Human babesiosis is an emerging tick-borne disease, caused by haemoprotozoa genus of Babesia. Cases of transfusion-transmitted and naturally acquired Babesia infection have been reported worldwide in recent years and causing a serious public health problem. Babesia duncani is one of the important pathogens of human babesiosis, which seriously endangers human health. The in vitro culture systems of B. duncani have been previously established, and it requires fetal bovine serum (FBS) to support long-term proliferation. However, there are no studies on serum-free in vitro culture of B. duncani. In this study, we reported that B. duncani achieved long-term serum-free culture in VP-SFM AGTTM (VP-SFM) supplemented with AlbuMaxTM I. The effect of adding different dilutions of AlbuMaxTM I to VP-SFM showed that 2 mg/mL AlbuMaxTM I had the best B. duncani growth curve with a maximum percentage of parasitized erythrocytes (PPE) of over 40%, and it can be used for long-term in vitro culture of B. duncani. However, the commonly used 20% serum-supplemented medium only achieves 20% PPE. Clearly, VP-SFM with 2 mg/mL AlbuMaxTM I (VP-SFMA) is more suitable for the in vitro proliferation of B. duncani. VP-SFM supplemented with CD lipid mixture was also tested, and the results showed it could support the parasite growth at 1:100 dilution with the highest PPE of 40%, which is similar to that of 2 mg/mL AlbuMaxTM I. However, the CD lipid mixture was only able to support the in vitro culture of B. duncani for 8 generations, while VP-SFMA could be used for long-term culture. To test the pathogenicity, the VP-SFMA cultured B. duncani was also subjected to hamster infection. Results showed that the hamster developed dyspnea and chills on day 7 with 30% PPE before treatment, which is similar to the symptoms with un-cultured B. duncani. This study develops a unique and reliable basis for further understanding of the physiological mechanisms, growth characteristics, and pathogenesis of babesiosis, and provides good laboratory material for the development of drugs or vaccines for human babesiosis and possibly other parasitic diseases.
Asunto(s)
Babesia , Babesiosis , Animales , Cricetinae , Humanos , Babesiosis/tratamiento farmacológico , Babesiosis/parasitología , Suero , Suplementos Dietéticos , Lípidos/farmacologíaRESUMEN
Under stressful conditions, black rhinoceroses that are sub-clinical carriers of Babesia bicornis can succumb to babesiosis. After 16 days in captivity, a five-year-old female black rhino captured for relocation presented with inappetence, abdominal discomfort and constipation. After chemical immobilisation, dry faecal balls were removed from the rectum, peripheral blood smears were made and blood collected into EDTA tubes. She was treated prophylactically for colic with flunixin meglumine, penicillin and doramectin. Piroplasms were seen on fixed and stained peripheral blood smears. Overnight she developed severe haemoglobinuria, a sign consistent with babesiosis. Subsequently, DNA extracted from a blood specimen reacted with the B. bicornis probe on Reverse Line Blot (RLB) assay, confirming the diagnosis of babesiosis. Specific treatment consisted of 14 ml imidocarb dipropionate (dosage 2.4 mg/kg) administered intramuscularly by pole syringe. Fifteen days later the patient was still moderately anaemic, with the red blood cell (RBC) count, haematocrit and haemoglobin concentration within normal ranges but on microscopic examination there was a marked RBC macrocytosis and polychromasia indicative of a regenerative anaemia. DNA extracted from blood collected at that time did not react with the B. bicornis probe on RLB assay, indicating that treatment with imidocarb had been effective. Once the patient's appetite improved, she started gaining weight. After 82 days in captivity and 65 days after babesiosis had been diagnosed, she was released at the site where she had been captured.
Asunto(s)
Babesia , Babesiosis , Femenino , Animales , Babesiosis/tratamiento farmacológico , Perisodáctilos , ADNRESUMEN
Babesiosis is an emerging zoonotic disease that is typically caused by Babesia microti infection. Clinical treatment of B. microti infection is challenging; hence, it is crucial to find new effective drugs. The current laboratory screening methods for anti-B. microti drugs are not optimized. We conducted drug-suppressive and drug-therapeutic tests to investigate whether use of an immunosuppressant and the target gene-based qPCR are helpful to reduce the number of animals affected and to improve parasite detection in an immunocompetent mouse model. These results were verified by subpassage test. In the drug-suppressive test, no B. microti were observed after immunosuppressant administration or in subpassage mice in the 100 mg/kg robenidine hydrochloride (ROBH) group. The opposite results were observed in the control, 50 mg/kg ROBH, atovaquone (ATO) + azithromycin (AZM), and proguanil hydrochloride (PGH) groups. Significant differences were observed in the EIR and target gene relative values (both P < 0.001) between the control group and any ROBH groups. In the drug-therapeutic test, recrudescence occurred in the 50 mg/kg ROBH, ATO+AZM, and control groups. This was not observed in the 100 mg/kg ROBH group after immunosuppressant administration. Similar findings were observed in the subpassage test. This suggests that a 4-day anti-B. microti drug-suppressive test can be used in preliminary drug screening. Potentially effective drugs can be verified by immunosuppressant test in subsequent drug-therapeutic tests. Thus, a laboratory evaluation method of anti-B. microti drug efficacy was optimized, which is highly accurate and requires a short drug screening time.
Asunto(s)
Babesia microti , Babesiosis , Preparaciones Farmacéuticas , Animales , Babesiosis/tratamiento farmacológico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , RatonesRESUMEN
Babesiosis is an infectious disease with an empty drug pipeline. A search inside chemical libraries for novel potent antibabesial candidates may help fill such an empty drug pipeline. A total of 400 compounds (200 drug-like and 200 probe-like) from the Malaria Box were evaluated in the current study against the in vitro growth of Babesia divergens (B. divergens), a parasite of veterinary and zoonotic importance. Novel and more effective anti-B. divergens drugs than the traditionally used ones were identified. Seven compounds (four drug-like and three probe-like) revealed a highly inhibitory effect against the in vitro growth of B. divergens, with IC50s ≤ 10 nanomolar. Among these hits, MMV006913 exhibited an IC50 value of 1 nM IC50 and the highest selectivity index of 32,000. The atom pair fingerprint (APfp) analysis revealed that MMV006913 and MMV019124 showed maximum structural similarity (MSS) with atovaquone and diminazene aceturate (DA), and with DA and imidocarb dipropionate (ID), respectively. MMV665807 and MMV665850 showed MMS with each other and with ID. Of note, a high concentration (0.75 IC50) of MMV006913 caused additive inhibition of B. divergens growth when combined with DA at 0.75 or 0.50 IC50. The Medicines for Malaria Venture box is a treasure trove of anti-B. divergens candidates according to the obtained results.
Asunto(s)
Babesia/efectos de los fármacos , Babesiosis/tratamiento farmacológico , Patógenos Transmitidos por la Sangre/efectos de los fármacos , Malaria/tratamiento farmacológico , Animales , Antiprotozoarios/farmacología , Atovacuona/farmacología , Babesia/patogenicidad , Babesiosis/parasitología , Diminazeno/análogos & derivados , Diminazeno/farmacología , Humanos , Imidocarbo/análogos & derivados , Imidocarbo/farmacología , Malaria/epidemiología , Malaria/parasitología , Plantas Medicinales/químicaRESUMEN
Babesia gibsoni is a tick-transmitted intraerythrocytic apicomplexan parasite that causes babesiosis in dogs. Due to the strong side effects and lack of efficacy of current drugs, novel drugs against B. gibsoni are urgently needed. Natural products as a source for new drugs is a good choice for screening drugs against B. gibsoni. The current study focuses on identifying novel potential drugs from natural products against B. gibsoniin vitro. Parasite inhibition was verified using a SYBR green I-based fluorescence assay. A total of 502 natural product compounds were screened for anti-B. gibsoni activity in vitro. Twenty-four compounds showed high growth inhibition (>80%) on B. gibsoni and 5 plant-derived compounds were selected for further study. The half-maximal inhibitory concentration (IC50) values of lycorine (LY), vincristine sulfate (VS), emetine·2HCl (EME), harringtonine (HT) and cephaeline·HBr (CEP) were 784.4 ± 3.3, 643.0 ± 2.8, 253.1 ± 1.4, 23.4 ± 1.2, and 108.1 ± 4.3 nM, respectively. The Madin-Darby canine kidney (MDCK) cell line was used to assess cytotoxicity of hit compounds. All compounds showed minimal toxicity to the MDCK cells. The effects of hit compounds combined with diminazene aceturate (DA) on B. gibsoni were further evaluated in vitro. VS, EME, HT or CEP combined with DA showed synergistic effects against B. gibsoni, whereas LY combined with DA showed an antagonistic effect against B. gibsoni. The results obtained in this study indicate that LY, VS, EME, HT and CEP are promising compounds for B. gibsoni treatment.
Asunto(s)
Antiprotozoarios/farmacología , Babesia/efectos de los fármacos , Productos Biológicos/farmacología , Diminazeno/análogos & derivados , Animales , Babesiosis/parasitología , Babesiosis/prevención & control , Diminazeno/farmacología , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/prevención & control , Perros , Evaluación Preclínica de Medicamentos , Concentración 50 InhibidoraRESUMEN
Babesia spp. are tick-transmitted intra-erythrocytic protozoan parasites that infect humans and animals, causing a flu-like illness and hemolytic anemia. There is currently no human vaccine available. People most at risk of severe disease are the elderly, immunosuppressed, and asplenic individuals. B. microti and B. divergens are the predominant species affecting humans. Here, we present a whole-parasite Babesia vaccine. To establish proof-of-principle, we employed chemically attenuated B. microti parasitized red blood cells from infected mice. To aid clinical translation, we produced liposomes containing killed parasite material. Vaccination significantly reduces peak parasitemia following challenge. B cells and anti-parasite antibodies do not significantly contribute to vaccine efficacy. Protection is abrogated by the removal of CD4+ T cells or macrophages prior to challenge. Importantly, splenectomized mice are protected by vaccination. To further facilitate translation, we prepared a culture-based liposomal vaccine and demonstrate that this performs as a universal vaccine inducing immunity against different human Babesia species.
Asunto(s)
Babesia microti/inmunología , Babesiosis/inmunología , Babesiosis/prevención & control , Evaluación Preclínica de Medicamentos , Parasitemia/inmunología , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/uso terapéutico , Animales , Anticuerpos Antiprotozoarios/sangre , Linfocitos B/inmunología , Babesiosis/parasitología , Sistemas de Liberación de Medicamentos/métodos , Femenino , Humanos , Inmunidad , Liposomas/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones SCID , Parasitemia/terapia , Linfocitopenia-T Idiopática CD4-Positiva/inmunología , Garrapatas/parasitologíaRESUMEN
BACKGROUND: Babesia bovis reproduces sexually in the gut of its tick vector Rhipicephalus microplus, which involves expression of 6cys A and 6cys B proteins. Members of the widely conserved 6cys superfamily are candidates for transmission blocking vaccines (TBV), but intricacies in the immunogenicity of the 6cys proteins in the related Plasmodium parasites required the identification of transmission blocking domains in these molecules for vaccine design. Hereby, the immunogenic efficacy of recombinant (r) B. bovis 6cys A and B proteins as a TBV formulation was studied. METHODS: The immunogenicity of r6cys A and 6cys B proteins expressed in a eukaryotic system was evaluated in a cattle immunization trial (3 immunized and 3 control calves). A B. bovis sexual stage induction in vitro inhibition assay to assess the ability of antibodies to block the production of sexual forms by the parasite was developed. RESULTS: Immunized cattle generated antibodies against r6cys A and r6cys B that were unable to block sexual reproduction of the parasite in ticks. Additionally, these antibodies also failed in recognizing native 6cys A and 6cys B and peptides representing 6cys A and 6cys B functional domains and in inhibiting the development of sexual forms in an in vitro induction system. In contrast, rabbit antibodies generated against synthetic peptides representing predicted B-cell epitopes of 6cys A and 6cys B recognized recombinant and native forms of both 6cys proteins as well as peptides representing 6cys A and 6cys B functional domains and were able to neutralize development of sexual forms of the parasite in vitro. CONCLUSIONS: These data, combined with similar work performed on Plasmodium 6cys proteins, indicate that an effective 6cys protein-based TBV against B. bovis will require identifying and targeting selected regions of proteins containing epitopes able to reduce transmission.
Asunto(s)
Babesia bovis/inmunología , Babesiosis/prevención & control , Enfermedades de los Bovinos/prevención & control , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/inmunología , Animales , Anticuerpos Antiprotozoarios/inmunología , Babesia bovis/genética , Babesia bovis/fisiología , Babesiosis/inmunología , Babesiosis/parasitología , Babesiosis/transmisión , Bovinos , Enfermedades de los Bovinos/parasitología , Enfermedades de los Bovinos/transmisión , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Proteínas Protozoarias/administración & dosificación , Proteínas Protozoarias/genética , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Conejos , Reproducción , Rhipicephalus/parasitología , Rhipicephalus/fisiologíaRESUMEN
Ticks are of great economic importance to humans and animals due to their role in disease transmission. The application of synthetic, chemical acaricides on the animal and/or the environment (the most used tick control method globally) has led to the selection of tick populations that are resistant. Their adverse effects on ecology and human and animal health cannot be overemphasised. As a result, the search for alternatives that are natural and can overcome these adverse effects are strongly indicated. Using gas chromatography-mass spectrometry (GC-MS) and adult immersion test (AIT), this study evaluated the chemical composition and acaricidal activity, respectively, of Eucalyptus globulus essential oil (EO) on Rhipicephalus (Boophilus) annulatus ticks. This is a major tick species implicated for the transmission of bovine piroplasmosis in Nigeria. The acaricidal activity was evaluated using different concentrations (0.625, 1.25, 2.5, 5 and 10%) of E. globulus EO. Amitraz (1 and 2%) and cypermethrin (2%) served as the positive control and 2% dimethylsulfoxide in distilled water was the negative control. Three replicates of 10 engorged female ticks each were immersed in the test samples for 2 min and the experiment was done twice. The GC-MS analysis identified the major constituents of E. globulus EO as eucalyptol (1,8-cineole) (78%), menthol (20%) and menthone (3%). Eucalyptus globulus EO caused 97% acaricidal mortality at 10% concentration. The lower concentrations reduced tick fecundity up to 90% in a dose-dependent manner. This study provides support for plant EOs as alternative tick control strategy for humans and animals.
Asunto(s)
Acaricidas , Babesiosis , Enfermedades de los Bovinos , Eucalyptus , Aceites Volátiles , Rhipicephalus , Animales , Bovinos , Aceite de Eucalipto , Femenino , Larva , Nigeria , Aceites Volátiles/farmacologíaRESUMEN
Babesia bovis parasites present a serious and significant health concern for the beef and dairy industries in many parts of the world. Difficulties associated with the current diagnostic techniques include the following: they are prone to human error (microscopy) or expensive and time-consuming (polymerase chain reaction) to perform. Little is known about the biochemical changes in blood that are associated with Babesia infections. The discovery of new biomarkers will lead to improved diagnostic outcomes for the cattle industry. Vibrational spectroscopic technologies can record a chemical snapshot of the entire organism and the surrounding cell thereby providing a phenotype of the organism and the host infected cell. Here, we demonstrate the applicability of vibrational spectroscopic imaging techniques including Atomic Force Microscopy Infrared (AFM-IR) and confocal Raman microscopy to discover new biomarkers for B. bovis infections. Furthermore, we applied Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) to detect B. bovis in red blood cells (RBCs). Based on changes in the IR spectral bands, with ATR-FTIR in combination with Partial Least Squares-Discriminant Analysis we were able to discriminate infected samples from controls with a sensitivity and specificity of 92.0% and 91.7%, respectively, in less than 2 min, excluding sample extraction and preparation. The proposed method utilized a lysis approach to remove hemoglobin from the suspension of infected and uninfected cells, which significantly increased the sensitivity and specificity compared to measurements performed on intact infected red blood cells (intact infected RBC, 77.3% and 79.2%). This work represents a holistic spectroscopic study from the level of the single infected RBC using AFM-IR and confocal Raman to the detection of the parasite in a cell population using ATR-FTIR for a babesiosis diagnostic.
Asunto(s)
Babesia bovis/química , Babesiosis/diagnóstico , Enfermedades de los Bovinos/diagnóstico , Espectrofotometría Infrarroja/métodos , Espectrometría Raman/métodos , Animales , Babesia bovis/aislamiento & purificación , Babesiosis/parasitología , Biomarcadores/química , Bovinos , Enfermedades de los Bovinos/parasitología , Análisis Discriminante , Eritrocitos/parasitología , Análisis de los Mínimos Cuadrados , Microscopía de Fuerza Atómica , Microscopía ConfocalRESUMEN
BACKGROUND: Persistent and relapsing babesiosis caused by Babesia microti often occurs in immunocompromised patients, and has been associated with resistance to antimicrobial agents such as atovaquone. Given the rising incidence of babesiosis in the United States, novel drugs are urgently needed. In the current study, we tested whether clofazimine (CFZ), an antibiotic used to treat leprosy and drug-resistant tuberculosis, is effective against B. microti. METHODS: Mice with severe combined immunodeficiency were infected with 107B. microti-infected erythrocytes. Parasites were detected by means of microscopic examination of Giemsa-stained blood smears or nested polymerase chain reaction. CFZ was administered orally. RESULTS: Uninterrupted monotherapy with CFZ curtailed the rise of parasitemia and achieved radical cure. B. microti parasites and B. microti DNA were cleared by days 10 and 50 of therapy, respectively. A 7-day administration of CFZ delayed the rise of parasitemia by 22 days. This rise was caused by B. microti isolates that did not carry mutations in the cytochrome b gene. Accordingly, a 14-day administration of CFZ was sufficient to resolve high-grade parasitemia caused by atovaquone-resistant B. microti parasites. CONCLUSIONS: Clofazimine is effective against B. microti infection in the immunocompromised host. Additional preclinical studies are required to identify the minimal dose and dosage of CFZ for babesiosis.
Asunto(s)
Babesia microti/efectos de los fármacos , Babesiosis/tratamiento farmacológico , Babesiosis/parasitología , Clofazimina/uso terapéutico , Huésped Inmunocomprometido , Leprostáticos/uso terapéutico , Secuencia de Aminoácidos , Animales , Babesia microti/genética , Babesia microti/inmunología , Babesiosis/inmunología , Clofazimina/administración & dosificación , Clofazimina/efectos adversos , Citocromos b/química , Citocromos b/genética , ADN Protozoario , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Resistencia a Medicamentos , Eritrocitos/parasitología , Leprostáticos/administración & dosificación , Leprostáticos/efectos adversos , Ratones , Parasitemia/parasitología , Resultado del TratamientoRESUMEN
The in vitro anti-Babesia canis activities of nine essential oils were investigated. Among the tested essential oils Achillea millefolium, Eugenia caryophyllus and Citrus grandis were the most active (IC50 values of 51.0, 60.3 and 61.3 µg/mL, respectively). The oils from Abies sibirica, Rosmarinus officinalis, Eucalyptus globulus, Cinnamonum zeylanicum, Mentha piperita and Pinus sylvestris were less active (IC50 values of 134.3, 237.3, 239.3, 367.9, 837.5 and 907.3 µg/mL, respectively). The results support the concept that some essential oil constituents may be useful in the clinical management of babesiosis.
Asunto(s)
Antibacterianos/farmacología , Babesia/efectos de los fármacos , Aceites Volátiles/farmacología , Aceites de Plantas/farmacología , Plantas/química , Babesiosis/tratamiento farmacológico , Concentración 50 Inhibidora , Aceites de Plantas/químicaRESUMEN
Absence of an effective high-throughput drug-screening system for Babesia parasites is considered one of the main causes for the presence of a wide gap in the treatment of animal babesiosis when compared with other hemoprotozoan diseases, such as malaria. Recently, a simple, accurate, and automatic fluorescence assay was established for large-scale anti-Babesia (B. bovis, B. bigemina, B. divergens, B. caballi and T. equi) drug screening. Such development will facilitate anti-Babesia drug discovery, especially in the post-genomic era, which will bring new chemotherapy targets with the completion of the Babesia genome sequencing project currently in progress. In this review, we present the current progress in the various assays for in vitro and in vivo anti-Babesia drug testing, as well as the challenges, highlighting new insights into the future of anti-Babesia drug screening.
Asunto(s)
Babesia/efectos de los fármacos , Babesiosis/tratamiento farmacológico , Evaluación Preclínica de Medicamentos/veterinaria , Evaluación Preclínica de Medicamentos/métodos , Técnicas In Vitro/métodos , Técnicas In Vitro/veterinariaRESUMEN
Berberis vulgaris (B. vulgaris) and Rhus coriaria (R. coriaria) have been documented to have various pharmacologic activities. The current study assessed the in vitro as well as in vivo inhibitory efficacy of a methanolic extract of B. vulgaris (MEBV) and an acetone extract of R. coriaria (AERC) on six species of piroplasm parasites. The drug-exposure viability assay was tested on three different cell lines, namely mouse embryonic fibroblast (NIH/3T3), Madin-Darby bovine kidney (MDBK) and human foreskin fibroblast (HFF) cells. Qualitative phytochemical estimation revealed that both extracts containing alkaloid, tannin, saponins and terpenoids and significant amounts of flavonoids and polyphenols. The GC-MS analysis of MEBV and AERC revealed the existence of 27 and 20 phytochemical compounds, respectively. MEBV and AERC restricted the multiplication of Babesia (B.) bovis, B. bigemina, B. divergens, B. caballi, and Theileria (T.) equi at the half-maximal inhibitory concentration (IC50) of 0.84 ± 0.2, 0.81 ± 0.3, 4.1 ± 0.9, 0.35 ± 0.1 and 0.68 ± 0.1 µg/mL and 85.7 ± 3.1, 60 ± 8.5, 90 ± 3.7, 85.7 ± 2.1 and 78 ± 2.1 µg/mL, respectively. In the cytotoxicity assay, MEBV and AERC inhibited MDBK, NIH/3T3 and HFF cells with half-maximal effective concentrations (EC50) of 695.7 ± 24.9, 931 ± 44.9, Ë1500 µg/mL and 737.7 ± 17.4, Ë1500 and Ë1500 µg/mL, respectively. The experiments in mice showed that MEBV and AERC prohibited B. microti multiplication at 150 mg/kg by 66.7% and 70%, respectively. These results indicate the prospects of these extracts as drug candidates for piroplasmosis treatment following additional studies in some clinical cases.
Asunto(s)
Antiprotozoarios/farmacología , Babesia/efectos de los fármacos , Babesiosis/tratamiento farmacológico , Berberis/química , Fitoquímicos/farmacología , Extractos Vegetales/farmacología , Rhus/química , Acetona/química , Animales , Babesiosis/parasitología , Femenino , Humanos , Metanol/química , Ratones , Ratones Endogámicos BALB CRESUMEN
Babesia (B.) bovis is one of the main etiological agents of bovine babesiosis, causes serious economic losses to the cattle industry. Control of bovine babesiosis has been hindered by the limited treatment selection for B. bovis, thus, new options are urgently needed. We explored the drug library and unbiasedly screened 640 food and drug administration (FDA) approved drug compounds for their inhibitory activities against B. bovis in vitro. The initial screening identified 13 potentially effective compounds. Four potent compounds, namely mycophenolic acid (MPA), pentamidine (PTD), doxorubicin hydrochloride (DBH) and vorinostat (SAHA) exhibited the lowest IC50 and then selected for further evaluation of their in vitro efficacies using viability, combination inhibitory and cytotoxicity assays. The half-maximal inhibitory concentration (IC50) values of MPA, PTD, DBH, SAHA were 11.38 ± 1.66, 13.12 ± 4.29, 1.79 ± 0.15 and 45.18 ± 7.37 µM, respectively. Of note, DBH exhibited IC50 lower than that calculated for the commonly used antibabesial drug, diminazene aceturate (DA). The viability result revealed the ability of MPA, PTD, DBH, SAHA to prevent the regrowth of treated parasite at 4 × and 2 × of IC50. Antagonistic interactions against B. bovis were observed after treatment with either MPA, PTD, DBH or SAHA in combination with DA. Our findings indicate the richness of FDA approved compounds by novel potent antibabesial candidates and the identified potent compounds especially DBH might be used for the treatment of animal babesiosis caused by B. bovis.
Asunto(s)
Antiprotozoarios/farmacología , Babesia bovis/efectos de los fármacos , Animales , Antiprotozoarios/toxicidad , Babesia bovis/crecimiento & desarrollo , Babesiosis/tratamiento farmacológico , Babesiosis/parasitología , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Enfermedades de los Bovinos/parasitología , Perros , Doxorrubicina/farmacología , Doxorrubicina/toxicidad , Aprobación de Drogas , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Ensayos Analíticos de Alto Rendimiento , Concentración 50 Inhibidora , Células de Riñón Canino Madin Darby/efectos de los fármacos , Ácido Micofenólico/farmacología , Ácido Micofenólico/toxicidad , Pentamidina/farmacología , Pentamidina/toxicidad , Bibliotecas de Moléculas Pequeñas , Espectrometría de Fluorescencia , Vorinostat/farmacología , Vorinostat/toxicidadRESUMEN
Diminazene aceturate (DA) and imidocarb dipropionate are commonly used in livestock as antipiroplasm agents. However, toxic side effects are common in animals treated with these two drugs. Therefore, evaluations of novel therapeutic agents with high efficacy against piroplasm parasites and low toxicity to host animals are of paramount importance. In this study, the 400 compounds in the Pathogen Box provided by the Medicines for Malaria Venture foundation were screened against Babesia bovis, Babesia bigemina, Babesia caballi, and Theileria equi. A fluorescence-based method using SYBR Green 1 stain was used for initial in vitro screening and determination of the half maximal inhibitory concentration (IC50). The initial in vitro screening performed using a 1⯵M concentration as baseline revealed nine effective compounds against four tested parasites. Two "hit" compounds, namely MMV021057 and MMV675968, that showed IC50â¯<â¯0.3⯵M and a selectivity index (SI)> 100 were selected. The IC50s of MMV021057 and MMV675968 against B. bovis, B. bigemina, T. equi and B. caballi were 23, 39, 229, and 146â¯nM, and 2.9, 3, 25.7, and 2.9â¯nM, respectively. In addition, a combination of MMV021057 and DA showed additive or synergistic effects against four tested parasites, while combinations of MMV021057 with MMV675968 and of MMV675968 with DA showed antagonistic effects. In mice, treated with 50â¯mg/kg MMV021057 and 25â¯mg/kg MMV675968 inhibited the growth of Babesia microti by 54 and 64%, respectively, as compared to the untreated group on day 8. Interestingly, a combination treatment with 6.25â¯mg/kg DA and 25â¯mg/kg MMV021057 inhibited B. microti by 91.6%, which was a stronger inhibition than that by single treatments with 50â¯mg/kg MMV021057 and 25â¯mg/kg DA, which showed 54 and 83% inhibition, respectively. Our findings indicated that MMV021057, MMV675968, and the combination treatment with MMV021057 and DA are prospects for further development of antipiroplasm drugs.
Asunto(s)
Antipruriginosos/administración & dosificación , Babesia/efectos de los fármacos , Babesiosis/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Eritrocitos/parasitología , Theileria/efectos de los fármacos , Theileriosis/tratamiento farmacológico , Animales , Babesia/fisiología , Babesiosis/sangre , Babesiosis/parasitología , Bovinos , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Humanos , Concentración 50 Inhibidora , Masculino , Ratones , Ratones Endogámicos BALB C , Theileria/fisiología , Theileriosis/sangre , Theileriosis/parasitologíaRESUMEN
BACKGROUND: There are no effective vaccines against Babesia and Theileria parasites; therefore, therapy depends heavily on antiprotozoal drugs. Treatment options for piroplasmosis are limited; thus, the need for new antiprotozoal agents is becoming increasingly urgent. Ellagic acid (EA) is a polyphenol found in various plant products and has antioxidant, antibacterial and effective antimalarial activity in vitro and in vivo without toxicity. The present study documents the efficacy of EA and EA-loaded nanoparticles (EA-NPs) on the growth of Babesia and Theileria. METHODS: In this study, the inhibitory effect of EA, ß-cyclodextrin ellagic acid (ß-CD EA) and antisolvent precipitation with a syringe pump prepared ellagic acid (APSP EA) was evaluated on four Babesia species and Theileria equi in vitro, and on the multiplication of B. microti in mice. The cytotoxicity assay was tested on Madin-Darby bovine kidney (MDBK), mouse embryonic fibroblast (NIH/3T3) and human foreskin fibroblast (HFF) cell lines. RESULTS: The half-maximal inhibitory concentration (IC50) values of EA and ß-CD EA on B. bovis, B. bigemina, B. divergens, B. caballi and T. equi were 9.58 ± 1.47, 7.87 ± 5.8, 5.41 ± 2.8, 3.29 ± 0.42 and 7.46 ± 0.6 µM and 8.8 ± 0.53, 18.9 ± 0.025, 11 ± 0.37, 4.4 ± 0.6 and 9.1 ± 1.72 µM, respectively. The IC50 values of APSP EA on B. bovis, B. bigemina, B. divergens, B. caballi and T. equi were 4.2 ± 0.42, 9.6 ± 0.6, 2.6 ± 1.47, 0.92 ± 5.8 and 7.3 ± 0.54 µM, respectively. A toxicity assay showed that EA, ß-CD EA and APSP EA affected the viability of cells with a half-maximal effective concentration (EC50) higher than 800 µM. In the experiments on mice, APSP EA at a concentration of 70 mg/kg reduced the peak parasitemia of B. microti by 68.1%. Furthermore, the APSP EA-atovaquone (AQ) combination showed a higher chemotherapeutic effect than that of APSP EA monotherapy. CONCLUSIONS: To our knowledge, this is the first study to demonstrate the in vitro and in vivo antibabesial action of EA-NPs and thus supports the use of nanoparticles as an alternative antiparasitic agent.
Asunto(s)
Antiprotozoarios/farmacología , Babesia microti/efectos de los fármacos , Babesia/efectos de los fármacos , Ácido Elágico/farmacología , Theileria/efectos de los fármacos , Animales , Babesia/crecimiento & desarrollo , Babesiosis/tratamiento farmacológico , Bovinos , Línea Celular , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/parasitología , Humanos , Concentración 50 Inhibidora , Ratones , Ratones Endogámicos BALB C , Nanopartículas/química , Extractos Vegetales/farmacología , Theileria/crecimiento & desarrollo , Theileriosis/tratamiento farmacológicoRESUMEN
BACKGROUND: Chemotherapy is a principle tool for the control and prevention of piroplasmosis. The search for a new chemotherapy against Babesia and Theileria parasites has become increasingly urgent due to the toxic side effects of and developed resistance to the current drugs. Chalcones have attracted much attention due to their diverse biological activities. With the aim to discover new drugs and drug targets, in vitro and in vivo antibabesial activity of trans-chalcone (TC) and chalcone 4 hydrate (CH) alone and combined with diminazene aceturate (DA), clofazimine (CF) and atovaquone (AQ) were investigated. METHODOLOGY/PRINCIPAL FINDINGS: The fluorescence-based assay was used for evaluating the inhibitory effect of TC and CH on four Babesia species, including B. bovis, B. bigemina, B. divergens, B. caballi, and T. equi, the combination with DA, CF, and AQ on in vitro cultures, and on the multiplication of a B. microti-infected mouse model. The cytotoxicity of compounds was tested on Madin-Darby bovine kidney (MDBK), mouse embryonic fibroblast (NIH/3T3), and human foreskin fibroblast (HFF) cell lines. The half maximal inhibitory concentration (IC50) values of TC and CH against B. bovis, B. bigemina, B. divergens, B. caballi, and T. equi were 69.6 ± 2.3, 33.3 ± 1.2, 64.8 ± 2.5, 18.9 ± 1.7, and 14.3 ± 1.6 µM and 138.4 ± 4.4, 60.9 ± 1.1, 82.3 ± 2.3, 27.9 ± 1.2, and 19.2 ± 1.5 µM, respectively. In toxicity assays, TC and CH affected the viability of MDBK, NIH/3T3, and HFF cell lines the with half maximum effective concentration (EC50) values of 293.9 ± 2.9, 434.4 ± 2.7, and 498 ± 3.1 µM and 252.7 ± 1.7, 406.3 ± 9.7, and 466 ± 5.7 µM, respectively. In the mouse experiment, TC reduced the peak parasitemia of B. microti by 71.8% when administered intraperitoneally at 25 mg/kg. Combination therapies of TC-DA and TC-CF were more potent against B. microti infection in mice than their monotherapies. CONCLUSIONS/SIGNIFICANCE: In conclusion, both TC and CH inhibited the growth of Babesia and Theileria in vitro, and TC inhibited the growth of B. microti in vivo. Therefore, TC and CH could be candidates for the treatment of piroplasmosis after further studies.
Asunto(s)
Antiprotozoarios/administración & dosificación , Babesia/efectos de los fármacos , Babesia/crecimiento & desarrollo , Babesiosis/tratamiento farmacológico , Chalconas/administración & dosificación , Theileria/efectos de los fármacos , Theileria/crecimiento & desarrollo , Theileriosis/tratamiento farmacológico , Animales , Antiprotozoarios/química , Babesia/genética , Babesiosis/parasitología , Línea Celular , Chalconas/química , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Concentración 50 Inhibidora , Ratones Endogámicos BALB C , Theileria/genética , Theileriosis/parasitologíaRESUMEN
Experimental study of a new paramagnetic complex Mn-DCTA is carried out. The complex (0.5 M manganese(II) solution with trans-1,2-diamine cyclohexane-N,N,N',N'-tetraacetic acid; Cyclomang) was used for contrast magnetic resonance imaging visualization of CNS involvement in dogs with severe forms of Babesia canis infection. CNS injuries were visualized in all cases, with highly intense contrasting at the expense of Mn-DCTA accumulation at the periphery of the damaged zone. Quantitative evaluation of the paramagnetic accumulation in the focus showed that the amplification index wa s 1.19±0.11 for the central areas and 1.47±0.17 for the peripheral ones. The pituitary (1.18±0.05) and vascular plexuses of the lateral ventricles (1.12±0.09) were also contrasted. Injection of the paramagnetic to dogs was not associated with any kinds of pathological or physiological reactions. Mn-DCTA complex allowed contrast visualization of the focal injuries to the CNS and could be regarded as a paramagnetic contrast agent for magnetic resonance imaging of brain injuries in dogs.
Asunto(s)
Babesiosis/diagnóstico por imagen , Encéfalo/diagnóstico por imagen , Enfermedades de los Perros/diagnóstico por imagen , Animales , Medios de Contraste/farmacocinética , Perros , Evaluación Preclínica de Medicamentos , Ácido Edético/análogos & derivados , Ácido Edético/farmacocinética , Imagen por Resonancia MagnéticaRESUMEN
Ticks are obligate haematophagous ectoparasites considered the principal vectors of disease among animals. Rhipicephalus microplus and R. annulatus ticks are the most important vectors for Babesia bigemina and B. bovis, two of the most important intraerythrocytic protozoan parasites species in cattle, responsible for babesiosis which together with anaplasmosis account for substantial economic losses in the livestock industry worldwide. Anti-tick vaccines are a proved alternative to traditional tick and tick borne diseases control methods but are still limited primarily due to the lack of effective antigens. Subsequently to the identification of antigens the validation is a laborious work often expensive. Tick artificial feeding, is a low cost alternative to test antigens allowing achieving critical data. Herein, R. microplus females were successfully artificially fed using capillary tubes. Calreticulin (CRT) protein, which in a previous study has been identified as being involved in B. bigemina infection in R. annulatus ticks, was expressed as recombinant protein (rCRT) in an E. coli expression system and antibodies raised against rCRT. Anti-rCRT serum was supplemented to a blood meal, offered to partially engorged R. microplus females and their effect in feeding process as well as infection by B. bigemina was analyzed. No significant reductions in tick and egg weight were observed when ticks fed with anti-rCRT serum. Furthermore, B. bigemina infection levels did not show a statistically significant decrease when ticks fed with anti-rCRT antibodies. Results suggest that CRT is not a suitable candidate for cattle vaccination trials.
Asunto(s)
Babesia/fisiología , Babesiosis/parasitología , Calreticulina/inmunología , Sueros Inmunes/inmunología , Rhipicephalus/parasitología , Animales , Babesia/inmunología , Secuencia de Bases , Bovinos , ADN Protozoario/genética , Femenino , Datos de Secuencia Molecular , Proteínas RecombinantesRESUMEN
The passive transfer of antibodies from dams to offspring via colostrum is believed to play an important role in protecting neonatal mammals from infectious disease. The study presented here investigates the uptake of colostrum by 548 calves in western Kenya maintained under smallholder farming, an important agricultural system in eastern Africa. Serum samples collected from the calves and dams at recruitment (within the first week of life) were analysed for the presence of antibodies to four tick-borne haemoparasites: Anaplasma marginale, Babesia bigemina, Theileria mutans and Theileria parva. The analysis showed that at least 89.33% of dams were seropositive for at least one of the parasites, and that 93.08% of calves for which unequivocal results were available showed evidence of having received colostrum. The maternal antibody was detected up until 21 weeks of age in the calves. Surprisingly, there was no discernible difference in mortality or growth rate between calves that had taken colostrum and those that had not. The results are also important for interpretation of serosurveys of young calves following natural infection or vaccination.